These considerations also highlight the need for a more robust database for compounds of environmental concern that activate PPAR-α, such as phthalates, perfluorinated acids, chlorinated solvents, and chloroacetic acids, either alone or in combinations relevant to human exposures.
We must be expeditious in drug development, which will ultimately lead to more robust preclinical testing of compounds and better concordance between laboratory groups.
Moreover, the assay seems to be more robust and more specific for detecting compounds with a pure androgenic mode of action.
We are not aware of any prior studies that extensively report on the presence of specific classes of medications based on toxicology at the time of death, a more robust approach that ensures that the compound was in fact being ingested.
With the growth of the additional chemical classes of compounds to be screened, a more robust model may be developed with the availability of biologically interesting small molecules from a diverse compound library.
Therefore, it has been suggested, as an alternative, to develop more robust and tolerant stains to toxic hydrolysate-related compounds so that it would be possible to simultaneously ferment the sugars within the hydrolysates in the presence of inhibitory compounds.
Therefore, we believe that the combination of our database and others would provide more robust information to estimate modes of action of anticancer compounds.
Generally speaking, a larger number of SqCC cell lines and an increased number of profiled compounds may be required to make more robust conclusions about the drug repurpose for SqCC subtypes.
For example, some fingerprints exhibit a significant ligand size dependency whereas others are more robust with respect to variations in the query or active compounds.
However, compounds with nonplanar rigid configuration have shown a more robust and greater selectivity for ERbeta than the planar ones [ 5].
